A phase II study evaluating bevacizumab in combination with fixed-dose rate gemcitabine and low-dose cisplatin for metastatic pancreatic cancer: is an anti-VEGF strategy still applicable? (Q40108015)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	A phase II study evaluating bevacizumab in combination with fixed-dose rate gemcitabine and low-dose cisplatin for metastatic pancreatic cancer: is an anti-VEGF strategy still applicable?	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

A phase II study evaluating bevacizumab in combination with fixed-dose rate gemcitabine and low-dose cisplatin for metastatic pancreatic cancer: is an anti-VEGF strategy still applicable? (English)

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

1 reference

based on heuristic

inferred from title

pancreatic cancer

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Andrew H Ko

1

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

Elizabeth Dito

2

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

Brian Schillinger

3

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

Alan P Venook

4

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

Zhidong Xu

5

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

Emily K Bergsland

6

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

Derrick Wong

7

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

Janet Scott

8

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

Jimmy Hwang

9

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

Margaret A Tempero

10

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

publication date

1 April 2008

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

Investigational New Drugs

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

26

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

463-471

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

A phase II study of fixed-dose rate gemcitabine plus low-dose cisplatin followed by consolidative chemoradiation for locally advanced pancreatic cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-008-9127-2

21 January 2018

Pancreatic cancer cell-derived vascular endothelial growth factor is biologically active in vitro and enhances tumorigenicity in vivo

1 reference

https://pubmed.ncbi.nlm.nih.gov/18379729

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Weekly gemcitabine and cisplatin chemotherapy: a well-tolerated but ineffective chemotherapeutic regimen in advanced pancreatic cancer patients. A report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD).

1 reference

https://pubmed.ncbi.nlm.nih.gov/18379729

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Enhanced expression of vascular endothelial growth factor in human pancreatic cancer correlates with local disease progression

1 reference

https://pubmed.ncbi.nlm.nih.gov/18379729

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II study of gemcitabine and cisplatin in the treatment of patients with advanced pancreatic carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/18379729

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase I clinical, plasma, and cellular pharmacology study of gemcitabine

1 reference

https://pubmed.ncbi.nlm.nih.gov/18379729

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Disseminated tumor cells in pancreatic cancer patients detected by immunocytology: a new prognostic factor

1 reference

https://pubmed.ncbi.nlm.nih.gov/18379729

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

In vitro interaction between gemcitabine and other anticancer drugs using a novel three-dimensional model.

1 reference

https://pubmed.ncbi.nlm.nih.gov/18379729

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Detection and prognostic impact of disseminated tumor cells in pancreatic carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/18379729

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale

1 reference

https://pubmed.ncbi.nlm.nih.gov/18379729

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Anti-tumor angiogenesis therapy using soluble receptors: enhanced inhibition of tumor growth when soluble fibroblast growth factor receptor-1 is used with soluble vascular endothelial growth factor receptor.

1 reference

https://pubmed.ncbi.nlm.nih.gov/18379729

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Evaluation and significance of circulating epithelial cells in patients with hormone-refractory prostate cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/18379729

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/18379729

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High expression of vascular endothelial growth factor is associated with liver metastasis and a poor prognosis for patients with ductal pancreatic adenocarcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/18379729

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/18379729

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Angiogenesis inhibitor TNP-470 reduces human pancreatic cancer growth

1 reference

https://pubmed.ncbi.nlm.nih.gov/18379729

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Gemcitabine potentiates cisplatin cytotoxicity and inhibits repair of cisplatin-DNA damage in ovarian cancer cell lines

1 reference

https://pubmed.ncbi.nlm.nih.gov/18379729

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Biological implications of tumor cells in blood and bone marrow of pancreatic cancer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/18379729

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Circulating tumor cells, disease progression, and survival in metastatic breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/18379729

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Gemcitabine and cisplatin in the treatment of advanced or metastatic pancreatic cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/18379729

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/18379729

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prognostic significance of angiogenesis in human pancreatic cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/18379729

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Synergistic interaction between cisplatin and gemcitabine in vitro.

1 reference

https://pubmed.ncbi.nlm.nih.gov/18379729

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ribozyme mediated cleavage of cell-associated isoform of vascular endothelial growth factor inhibits liver metastasis of a pancreatic cancer cell line

1 reference

https://pubmed.ncbi.nlm.nih.gov/18379729

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Disseminated tumour cells. Their detection and significance for prognosis of gastrointestinal and pancreatic carcinomas

1 reference

https://pubmed.ncbi.nlm.nih.gov/18379729

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pathways for aberrant angiogenesis in pancreatic cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/18379729

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacologically directed design of the dose rate and schedule of 2',2'-difluorodeoxycytidine (Gemcitabine) administration in leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/18379729

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial.

1 reference

https://pubmed.ncbi.nlm.nih.gov/18379729

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II study of fixed dose rate gemcitabine with cisplatin for metastatic adenocarcinoma of the pancreas

1 reference

https://pubmed.ncbi.nlm.nih.gov/18379729

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Gene therapy for pancreatic cancer using an adenovirus vector encoding soluble flt-1 vascular endothelial growth factor receptor

1 reference

https://pubmed.ncbi.nlm.nih.gov/18379729

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Gemcitabine combined with oxaliplatin in advanced pancreatic adenocarcinoma: final results of a GERCOR multicenter phase II study

1 reference

https://pubmed.ncbi.nlm.nih.gov/18379729

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Concomitant over-expression of vascular endothelial growth factor and its receptors in pancreatic cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/18379729

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cancer statistics, 2007

1 reference

https://pubmed.ncbi.nlm.nih.gov/18379729

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S10637-008-9127-2

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

Dimensions Publication ID

0 references

release_7l26hn7j7ngmnbzpnswhprsc2a

1 reference

https://api.fatcat.wiki/v0/release/7l26hn7j7ngmnbzpnswhprsc2a

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40108015&oldid=2203406953"